thrombin generation by monocytes (17). Monocyte vesiculation is one possible mechanism for the dissemination of membrane-associated procoagulant activity (18) . We recently reported that high levels of monocyte-derived microparticles (MDMPs) may be a marker for vasculopathies in diabetic patients, especially when diabetes-related nephropathy coexists (19) . The tissue factor-exposing MDMPs promote prothrombinase complex assembly, thereby facilitating intravascular generation of thrombin and enhanced procoagulant activity (20) . Thus, activated monocytes and vascular endothelial cells play important roles in the development of diabetic complications. However, to our knowledge, the effects of statin on MDMP in diabetes mellitus have not yet been studied.
In type 2 diabetes mellitus, the risks of nephropathy and cardiovascular complications increase, and the risk of renal failure increases in advanced stages of disease (21, 22) . Therefore, renal protection and cardioprotection are main therapeutic targets (23). The renal protective action of angiotensin-converting enzyme inhibitor (ACEI) in diabetes mellitus has widely been recognized (24), and the importance of angiotensin II in the pathogenesis of renal dysfunction has been inferred. Actually, it has already been shown that modulation of the renin-angiotensin system by angiotensin II receptor blocker (ARB) retards the progression of disease and protects the kidney in experimental models of diabetes mellitus (25). Losartan, a drug that blocks angiotensin type 1 receptors, also improves resistance vessel endothelial function in patients with type 2 diabetes mellitus (26), suggesting that at least part of the benefical effect of angiotensin II modulation is mediated through the angiotensin II/type 1 receptor pathway. In the present study, we investigated the effects of losartan and simvastatin on monocyte activation markers, MDMP and MCP-1, in patients with type 2 diabetes mellitus.
MATERIALS AND METHODS

Patients
The study group included 30 normotensive controls and 48 hypertensive patients. Controls were recruited from our hospital staff and other sources. Hypertensive patients admitted to our hospital between October 2000 and July 2002 for assessment of hypertension were recruited. None had inflammatory, coronary artery, or cerebrovascular disease within the previous 3 months or had clinically detectable renal, hepatic, infectious, or malignant disease. Anti-thrombotic agents, including aspirin, were withheld. Thirty of the hypertensive patients had type 2 diabetes mellitus and 18 did not. The criteria for the diagnosis of hypertension was a recumbent systolic blood pressure of > 150 mm Hg and recumbent diastolic pressure of > 90 mm Hg on 2 or more occasions (27 betes was defined according to American Diabetes Association Criteria (28). Hyperlipidemia was defined according to the Guidelines for Diagnosis and Treatment of Hyperlipidemias in Adults by the Japan Atherosclerosis Society (29). Table 1 shows the clinical characteristics of the hypertensive and control subjects.
Study Design
We administered Losartan (Banyu Pharmaceutical, Tokyo, Japan), 50 mg/day, to the hypertensive patients for 24 weeks. In addition, we administered simvastatin (Banyu Pharmaceutical), 10 mg/day, to the hyperlipidemic patients for 24 weeks. There were no other changes in any patient's pharmacologic regimen during losartan or simvastatin treatment. Clinical and biochemical data obtained before and after losartan or simvastatin administration were compared.
Assessment of MDMP
MDMP was detected by a previously reported method with some modifications (19). Ten microliters of washed intact platelets (3 × 10 8 /mL) was added to plasma, and the mixture was incubated with FITC-labeled Annexin V (FITC-Ann V) and phycoerythrin (PE)-labeled CD14 (PE-CD14) for 30 minutes in the dark at room temperature. Samples were diluted 1:10 with HEPES-Tyrode's buffer containing 5 mM/L EGTA and analyzed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostics).
Measurement of MCP-1, RANTES, sP-selectin, and sVCAM-1
Blood samples from patients and healthy controls were collected into tubes with sodium citrate or tubes without anticoagulant. Blood was allowed to clot at room temperature for a minimum of 1 hour. Serum or citrated plasma was isolated by centrifugation for 20 minutes at 1000 g at 4°C and then stored at -30°C until analysis. As positive controls in each assay, we used the recombinant products and standard solutions provided with the commercial kits. Levels of serum MCP-1, RANTES, sP-selectin, and sVCAM-1 were measured with a monoclonal antibodybased ELISA kit from R & D Systems according to the manufacturer's instructions.
Statistics
Data are presented as the mean ± SD. The significance of intergroup differences was determined by unpaired t test, and p values less than 0.05 were considered significant.
RESULTS
Levels of MDMP, chemokines (MCP-1 and RANTES)
, and soluble adhesion markers (sP-selectin and sVCAM-1) were different in the control group and the hypertension group ( Table 2) . Levels of MDMP, chemokines (MCP-1 and RANTES), and soluble adhesion markers (sP-selectin and sVCAM-1) also were different in hypertensive patients with and without type 2 diabetes mellitus ( Table 3) .
The systolic and diastolic blood pressures before losartan administration were similar in the subgroups of hypertensive patients with and without diabetes mellitus. However both the diastolic pressure and the systolic blood pressure decreased significantly in both subgroups after losartan administration ( Fig. 1 ).
The concentrations of MDMP, chemokines, and soluble adhesion markers in hypertensive patients with and without type 2 diabetes mellitus decreased significantly after losartan treatment (Table 4 ). On the other hand, the levels of MDMP, MCP-1, RANTES, and sP-selectin were unchanged in patients without diabetes, although the level of sVCAM-1 decreased.
The systolic and diastolic blood pressures decreased with monotherapy (losartan) and combination therapy (losartan and simvastatin) in the subgroups of hypertensive patients with diabetes mellitus (Fig. 2 ). MDMP, chemokines (MCP-1 and RANTES), and soluble adhesion markers (sP-selectin and sVCAM-1) all decreased after treatment in both subgroups of hypertensive patients with type 2 diabetes mellitus with both monotherapy and combination therapy ( Fig. 3 ). In particular, the decrease in MDMP with combination therapy was greater than that with monotherapy (p<0.05).
DISCUSSION
This study shows that angiotensin II is intimately related to vascular changes in type 2 diabetes mellitus. The development of hypertension in type 2 diabetes increases the risk of renal and cardiovascular disease (21). Therefore, normal-ization of hypertension is a key treatment goal for renal protection and possibly cardioprotection in type 2 diabetes (22). Inhibition of the renin-angiotensin system either by ACE inhibitors or angiotensin II antagonists has been shown to decrease structural renal damage (24). In this study, losartan decreased both systolic and diastolic pressures in hypertensive patients with and without type 2 diabetes mellitus. This finding suggests losartan may reduce renal and cardiovascular risks in hypertension with type 2 diabetes mellitus, and it agrees with other recent re- 1 . Systolic pressure and diastolic pressure before and after losartan administration to hypertensive patients with diabetes (n=30) and without diabetes (n=18). Data are shown as mean ± SD. SBP: systolic blood pressure; DBP: diastolic blood pressure.
FIG. 2.
Systolic pressure and diastolic pressure before and after monotherapy with losartan and combination therapy with losartan and simvastatin in patients with type 2 diabetes (n=30). Data are shown as mean ± SD. SBP: systolic blood pressure; DBP: diastolic blood pressure.
ports on losartan (30-32). However, ARB may have a beneficial effect on the vascular system beyond its anti-hypertensive action (33) (34) (35) (36) (37) (38) . Various factors are involved in diabetic vascular change, one of which is the monocytes/ macrophages (39) (40) (41) . Migration of monocytes into the vascular subendothelium occurs during the inflammatory response and plays a key role in the development of atherosclerosis (42) . Transendothelial monocyte migration is a multifactorial mechanism that initially involves adhesion of circulating monocytes to cytokine-regulated adhesion molecules expressed on the surface of endothelial cells (43) . Adherent monocytes then move through the endothelial cells toward specific chemokines and differentiate into tissue macrophages in the vessel wall (44) . Angiotensin II clearly is involved in this process (45) (46) (47) .
The present study found that the circulating concentration of MDMP, chemokines, and soluble adhesion molecules are higher in hypertensive patients with than without type 2 diabetes mellitus, and that the administration of an ARB decreased the concentrations of all these markers. MDMP is functionally a procoagulant factor, because it expresses surface tissue factor (18,19). On the other hand, it is possible to consider MDMP as a marker of monocyte activation (18). Recently we reported that the MDMP concentration is especially high in diabetic patients with nephropathy and suggested that the MDMP concentration may be a marker for nephropathy progression in type 2 diabetes (19). The ability of ARB to inhibit MDMP generation provides additional evidence of how deeply angiotensin II is involved in the pathogenesis of vascular change in type 2 diabetes. The similar improvement in circulating levels of chemokines and adhesion molecules after ARB administration provides confirmatory data and is consistent with previous reports (35, 45, 46) . Inhibition of angiotensin II-related vascular effects by ARB prevent some events in the genesis of atherosclerosis, such as decreasing the plasma levels of MCP-1 and sVACM-1, and therapy preventing the activation of monocytes (33, 34, 36) .
Combination therapy with losartan and simvastatin was synergistic in that MDMP decreased more with combination than monotherapy. It has been reported that statin is useful in the treatment of atherosclerosis because it disrupts the pathologic interactions between monocytes and endothelial cells (48) . For example, statin inhibits monocyte adhesion to the endothelium, the generation of inflammatory cytokines by monocytes, and the expression of adhesive molecules on both cells (49) (50) (51) (52) . Additionally, the inhibition of the prothrombotic state by statin prevents suppression of nitric oxide synthesis in endothelial cells, and consequently improves endothelial function (48, 53, 54) . Simvastatin especially suppresses tissue factor expression on monocytes and possesses an antiinflammatory effect, for example reducing the sensitivity to CRP (55) (56) (57) . The lowering of MDMP concentrations by combination therapy with statin and ARB is particularly interesting, because MDMP is important in the pathogenesis of type 2 diabetic nephropathy. The usefulness of this combination also was recently reported by Zoja and colleagues (58) . However, additional questions, such as how to identify the best candidates for combination therapy and issues related to the length of treatment require further study. Nevertheless, preliminary results indicate that combination therapy with statin and an ARB might be particularly potent anti-atherosclerotic therapy for patients with type 2 diabetes mellitus who have diabetic nephropathy. 
